Dr.Reddys announces commercial launch of 2-DG

Dr. Reddys, a leading multinational pharmaceutical company today announced the commercial launch of 2-deoxy-D-glucose (2-DG). Dr. Reddy’s will supply to major Government as well as private hospitals across the country. 

In the initial weeks, the Company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the other parts of the country.

The 2-DG manufactured by Dr. Reddy’s has a purity of 99.5 per cent and is being sold commercially under the brand name 2DGTM. The maximum retail price (MRP) of each sachet has been fixed at  990 rupees , with a subsidized



rate offered to Government institutions. Enquiries for 2DGTM can be sent to 2DG@drreddys.com.

2-DG was developed by the Institute of Nuclear Medicine and  Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s. 2-DG is an oral drug. It can be administered only upon preion and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care. Emergency use approval for anti-COVID-19 therapeutic application of the drug was granted on May 1.